Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

AusperBio Starts New Zealand Phase I Trial of Novel Therapy for CHB

publication date: Mar 10, 2023

AusperBio, a Hangzhou-Boston biopharma, has started a Phase I trial in New Zealand of its novel therapy for chronic hepatitis B. AHB-137 is a pan-genotypic antisense oligonucleotide (ASO) designed to target all HBV RNA. The company believes AHB-137 has the potential to be a best-in-class therapy. The first cohort of the trial, which enrolled adult healthy volunteers and chronic hepatitis B patients, did not report any major safety issues. AusperBio is dedicated to finding best-in-class therapeutics for HBV infections and to become a world leader in antiviral therapeutics. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital